Please login to the form below
infections
This page shows the latest infections news and features for those working in and with pharma, biotech and healthcare.
Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
Eli Lilly’s has announced that its neutralising antibody bamlanivimab significantly reduced the risk of COVID-19 infection among residents and staff in care homes.
Latest news
-
UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
Gilead’s antiviral drug scored an emergency use authorisation in May for use in patients hospitalised with a SARS-CoV-2 infection – the virus which causes COVID-19.
-
Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
They found that lateral flow kits would be effective in detecting up to 90% of COVID-19 infections that these individuals passed on to their contacts.
-
Trial combining British and Russian COVID-19 vaccines could begin in February
The interim analysis for efficacy of the vaccine, AZD1222, was based on 11, 636 participants with 131 symptomatic COVID-19 infections from the phase 3 UK and Brazil trials conducted by
-
Cambridge University develops DNA test for secondary infections in COVID-19 patients
This patient population is particular susceptible to further infections from bacteria and fungi that they may acquire in hospital – referred to as ‘ventilator-associated pneumonia’. ... The new test allows doctors to access the information they
-
UK pharmacies to begin administering COVID-19 vaccinations
infections had been reported.
More from news
Approximately 8 fully matching, plus 1,030 partially matching documents found.
Latest Intelligence
-
The search for effective drug treatments for COVID-19
Lastly, the two randomised, double-blind, placebo controlled clinical trials were conducted at multiple sites in Hubei province, China, where the infection was first described.
-
2021: the year of decentralisation in drug development
Whether decentralised or hybrid, amid pandemic stay-at-home mandates, their benefits become readily apparent to keep patients safe from viral infection and enrolled in studies by providing home healthcare options
-
Growing evidence supports the important role of biosimilars in healthcare
threatening infection.
-
Rethinking our approach to infectious disease preparedness
According to a paper in The Lancet, early research has found that nearly 15% of all COVID-19 patients acquire deadly secondary bacterial infections. ... With our relaunch as Infex Therapeutics this year, we are demonstrating an expanded focus to include
-
Exploring the potential of eosinophils
Much of this evidence has so far come from animal studies, which have identified that eosinophils help protect the body against bacterial, viral and parasitic infection, help maintain body weight, potentially
More from intelligence
Approximately 0 fully matching, plus 75 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
He was previously VP of clinical development and head of oncology and infection at AstraZeneca where he was responsible for building and managing the company's global oncology portfolio.
-
New faces at 90TEN, Lucid Group and Porterhouse
Cook joins 90TEN from Public Health England’s National Infection Service, where she worked as senior communications manager.
-
Recruiters PIR International appoint four new executives
George Owen (above) holds an MSc in Infection and Immunity from UCL and has direct industry experience.
-
Nabriva Therapeutics appoints chief medical officer
Jennifer Schranz will lead the company’s clinical development business. Nabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer
-
Nabriva Therapeutics appoints new chief commercial officer
Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for ... I am looking forward to working with
More from appointments
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. ... At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more
-
The patient journey: A long and winding road
because it helps to alleviate the fear of coronavirus infection that comes with in-person interaction.
-
October 2020: diversity and inclusion in clinical trials round-up
It’s been found that the implementation of newborn screening, infection prevention, and better coordination of care have led to improved survival.
-
The impact of COVID-19 on cancer care
In the height of the pandemic, cancer screening services were paused across the UK, both to protect individuals from COVID-19 infection and to enable the redeployment of healthcare professionals to ... 19 infection to patient health [8].
-
Patients are ready to embrace decentralised clinical trials, are you?
Identifying these potential infections early can help encourage individuals to seek care or self-isolate. ... Researchers are also using results from the app to investigate risk factors for infection, as well as the effects of COVID-19 on patients' health
More from PMHub
Approximately 1 fully matching, plus 52 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
